The D2 Antagonist Sulpiride Modulates the Neural Processing of Both Rewarding and Aversive Stimuli in Healthy Volunteers

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2011 Apr 16

PMID 21494790

Citations 19

Authors

Ciara McCabe

Anna Huber

Catherine J Harmer

Philip J Cowen

Affiliations

Soon will be listed here.

Abstract

Rationale: Animal studies indicate that dopamine pathways in the ventral striatum code for the motivational salience of both rewarding and aversive stimuli, but evidence for this mechanism in humans is less established. We have developed a functional magnetic resonance imaging (fMRI) model which permits examination of the neural processing of both rewarding and aversive stimuli.

Objectives: The aim of the study was to determine the effect of the dopamine receptor antagonist, sulpiride, on the neural processing of rewarding and aversive stimuli in healthy volunteers.

Methods: We studied 30 healthy participants who were randomly allocated to receive a single dose of sulpiride (400 mg) or placebo, in a double-blind, parallel-group design. We used fMRI to measure the neural response to rewarding (taste or sight of chocolate) and aversive stimuli (sight of mouldy strawberries or unpleasant strawberry taste) 4 h after drug treatment.

Results: Relative to placebo, sulpiride reduced blood oxygenation level-dependent responses to chocolate stimuli in the striatum (ventral striatum) and anterior cingulate cortex. Sulpiride also reduced lateral orbitofrontal cortex and insula activations to the taste and sight of the aversive condition.

Conclusions: These results suggest that acute dopamine receptor blockade modulates mesolimbic and mesocortical neural activations in response to both rewarding and aversive stimuli in healthy volunteers. This effect may be relevant to the effects of dopamine receptor antagonists in the treatment of psychosis and may also have implications for the possible antidepressant properties of sulpiride.

Citing Articles

Striatal dopamine D2/D3 receptor regulation of human reward processing and behaviour.

Osugo M, Wall M, Selvaggi P, Zahid U, Finelli V, Chapman G Nat Commun. 2025; 16(1):1852.

PMID: 39984436 PMC: 11845780. DOI: 10.1038/s41467-025-56663-7.

Dopamine has no direct causal role in the formation of treatment expectations and placebo analgesia in humans.

Kunkel A, Asan L, Kruger I, Erfurt C, Ruhnau L, Caliskan E PLoS Biol. 2024; 22(9):e3002772.

PMID: 39316644 PMC: 11421806. DOI: 10.1371/journal.pbio.3002772.

Effects of dopamine and opioid receptor antagonism on the neural processing of social and nonsocial rewards.

Massaccesi C, Korb S, Gotzendorfer S, Chiappini E, Willeit M, Lundstrom J Hum Brain Mapp. 2024; 45(4):e26645.

PMID: 38445523 PMC: 10915723. DOI: 10.1002/hbm.26645.

Effects of a single dose of amisulpride on functional brain changes during reward- and motivation-related processing using task-based fMRI in healthy subjects and patients with major depressive disorder - study protocol for a randomized clinical....

Carstens L, Popp M, Keicher C, Hertrampf R, Weigner D, Meiering M Trials. 2023; 24(1):761.

PMID: 38012795 PMC: 10683198. DOI: 10.1186/s13063-023-07788-x.

Neuromolecular Underpinnings of Negative Cognitive Bias in Depression.

Noworyta K, Cieslik A, Rygula R Cells. 2021; 10(11).

PMID: 34831380 PMC: 8621066. DOI: 10.3390/cells10113157.

References

McCabe C, Cowen P, Harmer C . Neural representation of reward in recovered depressed patients. Psychopharmacology (Berl). 2009; 205(4):667-77. PMC: 2718193. DOI: 10.1007/s00213-009-1573-9. View

Horder J, Harmer C, Cowen P, McCabe C . Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers. Int J Neuropsychopharmacol. 2010; 13(8):1103-13. DOI: 10.1017/S1461145710000453. View

Maia T, Frank M . From reinforcement learning models to psychiatric and neurological disorders. Nat Neurosci. 2011; 14(2):154-62. PMC: 4408000. DOI: 10.1038/nn.2723. View

Lewis D . Neural circuitry of the prefrontal cortex in schizophrenia. Arch Gen Psychiatry. 1995; 52(4):269-73; discussion 277-8. DOI: 10.1001/archpsyc.1995.03950160019004. View

Rolls E, Kringelbach M, de Araujo I . Different representations of pleasant and unpleasant odours in the human brain. Eur J Neurosci. 2003; 18(3):695-703. DOI: 10.1046/j.1460-9568.2003.02779.x. View

Beck A, Ward C, Mendelson M, Mock J, ERBAUGH J . An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561-71. DOI: 10.1001/archpsyc.1961.01710120031004. View

Lecrubier Y, Boyer P, Turjanski S, Rein W . Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord. 1997; 43(2):95-103. DOI: 10.1016/s0165-0327(96)00103-6. View

Strauss G, Frank M, Waltz J, Kasanova Z, Herbener E, Gold J . Deficits in positive reinforcement learning and uncertainty-driven exploration are associated with distinct aspects of negative symptoms in schizophrenia. Biol Psychiatry. 2010; 69(5):424-31. PMC: 3039035. DOI: 10.1016/j.biopsych.2010.10.015. View

McCabe C, Mishor Z, Cowen P, Harmer C . Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry. 2009; 67(5):439-45. PMC: 2828549. DOI: 10.1016/j.biopsych.2009.11.001. View

10.

Kahnt T, Heinzle J, Park S, Haynes J . The neural code of reward anticipation in human orbitofrontal cortex. Proc Natl Acad Sci U S A. 2010; 107(13):6010-5. PMC: 2851854. DOI: 10.1073/pnas.0912838107. View

11.

Abler B, Erk S, Walter H . Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI study. Psychopharmacology (Berl). 2007; 191(3):823-33. DOI: 10.1007/s00213-006-0690-y. View

12.

Kringelbach M, ODoherty J, Rolls E, Andrews C . Activation of the human orbitofrontal cortex to a liquid food stimulus is correlated with its subjective pleasantness. Cereb Cortex. 2003; 13(10):1064-71. DOI: 10.1093/cercor/13.10.1064. View

13.

Palminteri S, Lebreton M, Worbe Y, Grabli D, Hartmann A, Pessiglione M . Pharmacological modulation of subliminal learning in Parkinson's and Tourette's syndromes. Proc Natl Acad Sci U S A. 2009; 106(45):19179-84. PMC: 2776465. DOI: 10.1073/pnas.0904035106. View

14.

Rolls E, Grabenhorst F, Parris B . Neural systems underlying decisions about affective odors. J Cogn Neurosci. 2009; 22(5):1069-82. DOI: 10.1162/jocn.2009.21231. View

15.

Schultz W . Dopamine signals for reward value and risk: basic and recent data. Behav Brain Funct. 2010; 6:24. PMC: 2876988. DOI: 10.1186/1744-9081-6-24. View

16.

Schultz W . Multiple functions of dopamine neurons. F1000 Biol Rep. 2010; 2. PMC: 2948345. DOI: 10.3410/B2-2. View

17.

Fawcett J, Clark D, Scheftner W, Gibbons R . Assessing anhedonia in psychiatric patients. Arch Gen Psychiatry. 1983; 40(1):79-84. DOI: 10.1001/archpsyc.1983.01790010081010. View

18.

WATSON D, Clark L, Tellegen A . Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988; 54(6):1063-70. DOI: 10.1037//0022-3514.54.6.1063. View

19.

Zald D, Hagen M, Pardo J . Neural correlates of tasting concentrated quinine and sugar solutions. J Neurophysiol. 2002; 87(2):1068-75. DOI: 10.1152/jn.00358.2001. View

20.

Menon M, Jensen J, Vitcu I, Graff-Guerrero A, Crawley A, Smith M . Temporal difference modeling of the blood-oxygen level dependent response during aversive conditioning in humans: effects of dopaminergic modulation. Biol Psychiatry. 2007; 62(7):765-72. DOI: 10.1016/j.biopsych.2006.10.020. View